Intravenous Injection of Autologous Bone Marrow Derived Mononuclear Cells in Ischemic Stroke Patients in Iraq

Abdul Majeed Alwan Hammadi¹ and Fizel Abbas Al-himyari²

DOI: 10.26717/BJSTR.2017.01.000113

Received: May 17, 2017   Published: May 31, 2017

To view the Full Article   Peer-reviewed Article PDF

Abstract

Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. Mortality rate is about 20% and another third are left with permanent disability. Treatments for stroke are based on methods that restore the flow of blood to the brain, such as clot-busting enzymes, surgery, and drugs for thinning blood, stopping clots and protecting neurons. Scientists believe that mesenchymal stem cell protection may be due to secretion of growth factors that promote growth of new neurons, regulate the immune system and stimulate the formation of new blood vessel, Or due to neurogenesis. Autologous bone marrow derived mononuclear cells with closed method is very near to minimal manipulation and low risk procedure.

In this study, we aspirated 100 cc (mean volume) of bone marrow from 50 Iraqi adult patients (age ranges 34-86 years) (12 females 38 male) after filtration we injected 40 cc volume intravenously, mononuclear cell count was =5-6x10 7per product. The time from diagnosis till procedure performance was (3months-5 years), The effect of intravenous administration of autologous bone marrow mononuclear cells (BMMNCs) lead to improvement in European scale for stroke (+4-20) in 28 patients out of 50 (56%) in 4-8 weeks ). This study shows the positive effect of autologous bone marrow derived mononuclear cells in the functional recovery of adult patients with chronic ischemic stroke.

Keywords: Autologous; Bone marrow; Mononuclear cells; Stroke; Intravenous

Introduction | Patients and Methods | Results | Discussion | References |